…40.4%, and 56.8% versus 77.3% respectively (p<0.001). At four years the median survival was significantly shorter for those with frailty (adjusted HR 1.66; 95% CI 1.54 to 1.80). These data…
…CI 1.2-3.6, p=0.01) and for “GOLD COPD patients” (adjusted HR 2.0, 95% CI 1.0-3.7, p=0.04). Since COPD and heart failure present with similar symptoms and frequently do coexist, the clinical…
…Over-oxygenation was common and was significantly more likely to occur on non-respiratory ward admissions (76% vs 57%, p=0.03) (Anderson 2020). In Wellington, New Zealand, an audit of patients with an…
…usual care (92.7% vs 70.1% p<0.001) (OR 4.14, 95% CI 2.14 to 8.03). Further studies with larger cohorts in other healthcare settings are required before this approach can be recommended….
…CI;11.6-12.5) compared with 7.4 (95%CI 7.1-7.6) [evidence level III-2]. The natural history of COPD is characterised by progressive deterioration with episodes of acute deterioration in symptoms referred to as exacerbation….
…smoking cessation 12 weeks following the end of treatment compared to placebo, although abstinence was not objectively confirmed in all studies (NNT = 12, 95% CI 6 to 32). There…
…to hospital within the next 1 to 6 months (risk ratio=0.76, 95% CI 0.59 to 0.99) [evidence level I]. There was no significant difference in mortality (risk ratio=0.65, 95% CI…
…risk (RR 0.63, 95% CI 0.57 to 0.71). Despite significant heterogeneity, sensitivity analysis did not change the outcome [evidence level III-2]. Moreover, beta-blocker treatment did not diminish the beneficial effects…
…pneumonia (95% CI 15-74) and vaccination also reduces the likelihood of an exacerbation of COPD (OR 0.6 (95% CI 0.39-0.93)), NNT of 8 to prevent one exacerbation (95% CI 5-58)…